Welcome to our dedicated page for CRISPR Therapeutics news (Ticker: CRSP), a resource for investors and traders seeking the latest updates and insights on CRISPR Therapeutics stock.
CRISPR Therapeutics AG (symbol: CRSP) is a pioneering gene editing company dedicated to the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. This revolutionary technology allows for precise, directed changes to genomic DNA, enabling the treatment of genetically defined diseases.
The company's portfolio spans a broad range of therapeutic programs, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. One of its notable achievements is the development and approval of Casgevy, a therapeutic targeting sickle cell disease and transfusion-dependent beta-thalassemia, developed in collaboration with Vertex Pharmaceuticals.
To bolster its research and development, CRISPR Therapeutics has forged strategic partnerships with renowned companies such as Bayer, Vertex Pharmaceuticals, and ViaCyte, Inc. These collaborations aim to accelerate and expand the company's efforts in bringing novel therapies to market.
Headquartered in Zug, Switzerland, CRISPR Therapeutics operates through its wholly-owned U.S. subsidiary, with R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California, and London, United Kingdom.
The company's ongoing projects include advancing gene editing programs in immuno-oncology and developing stem cell-derived therapies for the treatment of Type 1 diabetes. With its innovative approach and strategic collaborations, CRISPR Therapeutics is at the forefront of the gene editing revolution, poised to make significant impacts in the field of medicine.
For more information, please visit www.crisprtx.com.
Vertex Pharmaceuticals and CRISPR Therapeutics announced the acceptance of two abstracts for presentation at the EHA 2021 Virtual Congress. The studies focus on CTX001, a gene-editing therapy for Sickle Cell Disease (SCD) and Transfusion-Dependent Beta-Thalassemia (TDT). Both abstracts detail safety and efficacy results from ongoing clinical trials, with data on patients showing promising follow-up outcomes. CTX001 aims to alleviate severe symptoms by increasing fetal hemoglobin levels, potentially reducing transfusion needs and sickle crises.
CRISPR Therapeutics and Nkarta have announced a strategic partnership to co-develop gene-edited cell therapies for cancer. The collaboration will focus on two chimeric antigen receptor (CAR) NK cell product candidates targeting CD70 and a novel NK+T product. Nkarta obtains a license for CRISPR gene editing technology for its NK cell therapies. Both companies will equally share R&D costs and profits, with a three-year exclusivity period for allogeneic, gene-edited NK cells. This partnership aims to accelerate the development of new cancer therapies, leveraging their expertise.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences. The Truist Securities Life Sciences Summit is set for May 5, 2021, at 11:20 a.m. ET. Following that, the 2021 Bank of America Healthcare Conference will occur on May 12, 2021, at 2:00 p.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-presentation. CRISPR Therapeutics focuses on gene-based medicines, leveraging its proprietary CRISPR/Cas9 technology across various disease areas.
CRISPR Therapeutics (Nasdaq: CRSP) announced a Trials in Progress poster presentation for its ongoing Phase 1 CARBON trial at the American Society of Clinical Oncology Annual Meeting. The presentation will cover the safety and efficacy of CTX110™, an allogeneic CAR-T investigational therapy targeting CD19, for treating relapsed or refractory B-cell malignancies. The virtual event will occur from June 4 to 8, 2021, with the poster session scheduled for 9:00 AM ET on June 4.
CRISPR Therapeutics (Nasdaq: CRSP) announced it received Priority Medicines designation from the European Medicines Agency for CTX001™, a gene-edited therapy for transfusion-dependent beta thalassemia (TDT). Over 30 patients have been dosed in ongoing trials, with enrollment completion expected in 2021. The company's financial results for Q1 2021 showed a net loss of $113.2 million, an increase from $69.7 million the previous year, and R&D expenses rose to $90.6 million. CRISPR also amended its agreement with Vertex for CTX001, sharing costs and profits 40/60.
BOSTON and CAMBRIDGE, Mass. and ZUG, Switzerland, April 26, 2021 – Vertex Pharmaceuticals and CRISPR Therapeutics announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to CTX001, a CRISPR/Cas9 gene-edited therapy for transfusion-dependent beta thalassemia (TDT). This designation aims to expedite the development and evaluation of innovative therapies.
CTX001 has also received multiple FDA designations and is currently being evaluated in ongoing clinical trials for TDT and severe sickle cell disease (SCD).
Vertex Pharmaceuticals and CRISPR Therapeutics have revised their collaboration agreement for CTX001, a CRISPR/Cas9-based gene editing therapy aimed at treating sickle cell disease and beta-thalassemia. Vertex will lead the development, manufacturing, and commercialization of CTX001, responsible for 60% of program costs and profits. CRISPR will receive a $900 million upfront payment and up to $200 million upon regulatory approval. Vertex sees significant commercial potential in CTX001, having dosed over 30 patients with encouraging clinical results.
CRISPR Therapeutics (Nasdaq: CRSP) announced promising preclinical data from its allogeneic CAR-T program at the AACR Annual Meeting 2021. The study showcased that CAR-T cells with CD70 knockout displayed enhanced potency and persistence compared to conventional CAR-T cells. The research explored the effects of CRISPR/Cas9 gene editing on various checkpoint genes, revealing CD70's superior efficacy. The ongoing clinical trials of CTX130, targeting CD70-expressing tumors, expect to report top-line data in 2021, marking a significant step in cancer treatment innovation.
CRISPR Therapeutics (Nasdaq: CRSP) announced participation in the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 9:30 a.m. ET. Members of the senior management team will represent the company.
A live webcast will be available on the company's Investors page, with a replay archived for 14 days following the event. CRISPR Therapeutics is focused on developing gene-based medicines using its proprietary CRISPR/Cas9 platform, targeting serious diseases across various fields.
CRISPR Therapeutics (Nasdaq: CRSP) will present a poster at the AACR Annual Meeting, focusing on a novel approach to augment CAR-T cell function through CD70 knockout technology. The presentation is scheduled for April 10, 2021, at 8:30 a.m. ET. This virtual event will showcase advancements in immunology and the potential of CRISPR's gene-editing platform. The company aims to develop transformative medicines for serious diseases, leveraging collaborations with industry leaders like Bayer and Vertex Pharmaceuticals.
FAQ
What is the current stock price of CRISPR Therapeutics (CRSP)?
What is the market cap of CRISPR Therapeutics (CRSP)?
What is CRISPR Therapeutics AG?
What does the CRISPR/Cas9 platform do?
Where is CRISPR Therapeutics headquartered?
What is Casgevy?
What types of diseases is CRISPR Therapeutics targeting?
Who are CRISPR Therapeutics' key partners?
What are some of CRISPR Therapeutics' current projects?
Where are CRISPR Therapeutics' R&D operations based?
How has CRISPR Therapeutics impacted the field of medicine?
Where can I find more information about CRISPR Therapeutics?
